Heparinoid Anticoagulation and Topical Fibrin Sealant in Heparin-Induced Thrombocytopenia

Jackson, Mark R.; Danby, Christopher A.; Alving, Barbara M.

doi:10.1016/s0003-4975(97)01065-5

Cited by 21 publications

(5 citation statements)

References 6 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In those situations in which heparin cannot be used, danaparoid sodium (Orgaran) can be considered. 9,29,40,41 The anticoagulant activity of danaparoid has been monitored successfully with the aPTT using a sensitive reagent 42 and also with an acti vated clotting time (ACT). 40 Danaparoid cannot be neu tralized by protamine sulfate.…”

Section: Prevention and Treatment Of Heparin-induced Thrombocytopeniamentioning

confidence: 99%

“…9,29,40,41 The anticoagulant activity of danaparoid has been monitored successfully with the aPTT using a sensitive reagent 42 and also with an acti vated clotting time (ACT). 40 Danaparoid cannot be neu tralized by protamine sulfate. Of 47 patients who have undergone bypass with danaparoid as the anticoagulant, 17 have been returned to the operating room for exces sive bleeding.…”

Section: Prevention and Treatment Of Heparin-induced Thrombocytopeniamentioning

confidence: 99%

“…41 In one patient, highly purified fibrin sealant (prepared by Baxter/American Red Cross) was obtained for compassionate use as one means to ensure adequate localized hemostasis in bypass surgery with danaparoid. 40 In the future, patients may receive specific thrombin in hibitors initially and then subcutaneous danaparoid until they are able to receive adequate anticoagulation with warfarin. Thus, several options will be available for pa tients with HIT, and the devastating consequences of continued thrombosis can potentially be completely avoided.…”

Section: Prevention and Treatment Of Heparin-induced Thrombocytopeniamentioning

confidence: 99%

See 2 more Smart Citations

Recognition and Management of Heparin-Induced Thrombocytopenia (HIT) and Thrombosis

Alving¹,

Krishnamurti²

1997

Semin Thromb Hemost

View full text Add to dashboard Cite

An immune response to heparin, which is clinically manifested by the development of thrombocytopenia with or without thrombosis, is stimulated by a complex of heparin with platelet factor 4 (PF4). The primary thrombotic events in patients with heparin-induced thrombocytopenia (HIT) are more frequently venous than arterial. The development of antibodies, however, does not always result in thrombocytopenia or in catastrophic events. The antibodies, which are of the IgG, IgM, and IgA isotypes, can be easily measured by an ELISA that contains a complex of heparin-platelet factor 4 (PF4). Initial antibody formation can be greatly reduced by limiting the exposure to unfractionated heparin or by the use of low-molecular-weight heparin. For those patients who require anticoagulation and who have antibodies to heparin-PF4, danaparoid (Orgaran), a low-molecular weight heparinoid that does not react with the antibodies, is now commercially available; argatroban, a thrombin-specific inhibitor, can also be obtained for compassionate use. The use of these agents during anticoagulation with warfarin is preferable to the simple discontinuation of heparin and intitiation of warfarin, because the latter treatment can result in ongoing thrombosis.

show abstract

Section: Prevention and Treatment Of Heparin-induced Thrombocytopeniamentioning

confidence: 99%

Section: Prevention and Treatment Of Heparin-induced Thrombocytopeniamentioning

confidence: 99%

Section: Prevention and Treatment Of Heparin-induced Thrombocytopeniamentioning

confidence: 99%

See 1 more Smart Citation

Recognition and Management of Heparin-Induced Thrombocytopenia (HIT) and Thrombosis

Alving¹,

Krishnamurti²

1997

Semin Thromb Hemost

View full text Add to dashboard Cite

show abstract

“…Anticoagulants are the mainstay therapy in the treatment and preventing the recurrence of thrombotic events concomitant to pulmonary embolism, deep vein thrombosis, myocardial infarction, unstable angina, rheumatic heart disease, vascular surgery, prosthetic heart valve, retinal vessel thrombosis, extra corpuscular circulation, hemodialysis, defibrination syndrome and infection‐induced thrombosis. [ 1,2 ]…”

Section: Introductionmentioning

confidence: 99%

Anticoagulant drug utilization pattern and their cost analysis: a retrospective study from Saudi Arabia

Ali¹,

Ahmad²,

Banu³

et al. 2020

Journal of Pharmaceutical Health Services Research

View full text Add to dashboard Cite

Objective The study was aimed to evaluate the cost and drug utilization pattern of anticoagulant drugs in a clinical setting in Saudi Arabia. Method A cross‐sectional retrospective study was conducted in a private hospital in Saudi Arabia. World Health Organization, defined daily dose, and American Society of Hematology methods were used to compute the daily price of each anticoagulant agent. Key findings Consumption of oral anticoagulants was very less as compared to the parenteral. Apixaban was the most prescribed oral drug, while enoxaparin sodium was the drug of choice among the parenteral. In oral anticoagulants, the unit‐wise cost was found to be highest for Rivaroxaban (12.60 SR (3.36 USD) and less for Warfarin (0.82 SR (0.22 USD)). Heparin sodium cost (51.62 SR (13.76 USD) was found to be the most expensive parenteral agent while the least expensive was Phytomenadione (3.76 SR (1.00 USD)). Conclusion Apixaban was the preferred oral anticoagulant among all the studied anticoagulants, although Warfarin is the cheapest. Therapeutic drug monitoring was recommended for Warfarin. The study highlights the importance of more studies to measure the advantages and disadvantages of all types of anticoagulants.

show abstract

“…Indicators will give data to health care managers regarding drug use, prescribing habits & important views of patient care. 1 The drugs capable of preventing alcohol-related injury or limiting and repairing damage already sustained might play an important role in the management of alcoholic patients. A number of socalled hepatoprotective agents are available and are extensively used, however the evidence that their use without abstinence conferring any benefits is poor 2 .…”

Section: Introductionmentioning

confidence: 99%

A Prospective Observational Study on Effects of Hepatoprotective Agents in Alcoholic Liver Disease at a Tertiary Care Hospital

Ahmed

Naseem

Unnisa

et al. 2018

J. Drug Delivery Ther.

View full text Add to dashboard Cite

Drug utilization evaluation of hepatoprotective drugs is important in view of the spectrum of effect and associated risks with their therapy. The study was designed to evaluate the effects and adverse effects of hepatoprotective agents. A prospective, observational study was carried out for a period of 6 months at Osmania General Hospital (a tertiary care hospital). 120 patients were evaluated receiving corticosteroids, pentoxifylline, ursodeoxycholic acid for observing a trend in hepatic parameters and its outcomes. Ursodeoxycholic acid (81.66%) was the most commonly prescribed drug in almost all cases of alcoholic liver diseases followed by pentoxifylline (10%) in hepatorenal syndrome and then prednisolone (8.33%) in fatty liver. 67 cases were reported to have the significant drop in liver transaminases and bilirubin levels. Ursodeoxycholic acid resulted in a drop of 25% serum bilirubin and 35% drop in serum ALT (alanine transaminase) and 33% drop in serum AST (aspartate transaminase) in patients in a time gap of 1 week. Among 120 cases 94 were males (78.05%) and 26 females (21.04%) and maximum patients with alcoholic liver disease belonged to age group of 30-40 years (27.6%). Ursodeoxycholic acid (300 mg once daily) is used as an off-label drug for all types of alcoholic liver disease and also for viral hepatitis. Though Ursodeoxycholic acid showed a significant drop in liver transaminases and serum bilirubin levels in cirrhotic patients a better alternative lie in liver transplantation as long as they remain abstinent from alcohol.

show abstract

Heparinoid Anticoagulation and Topical Fibrin Sealant in Heparin-Induced Thrombocytopenia

Cited by 21 publications

References 6 publications

Recognition and Management of Heparin-Induced Thrombocytopenia (HIT) and Thrombosis

Recognition and Management of Heparin-Induced Thrombocytopenia (HIT) and Thrombosis

Anticoagulant drug utilization pattern and their cost analysis: a retrospective study from Saudi Arabia

A Prospective Observational Study on Effects of Hepatoprotective Agents in Alcoholic Liver Disease at a Tertiary Care Hospital

Contact Info

Product

Resources

About